Mode
Text Size
Log in / Sign up

Late-onset BK polyomavirus nephropathy can occur years after kidney transplant without intensified immunosuppressionLate BK Virus Can Harm Kidney Transplants Years Later

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider late-onset BKPyVAN in kidney transplant recipients with allograft dysfunction years after transplant, even without intensified immunosuppression.

This case report presents 2 kidney transplant recipients who developed late-onset BK polyomavirus-associated nephropathy (BKPyVAN) at 9 years and 3 years post-transplant, respectively, while receiving dual immunosuppression with tacrolimus and mycophenolic acid. Both cases developed BKPyVAN without a history of intensified immunosuppression. After reduction of immunosuppression, both patients experienced gradual decline in allograft function associated with persistent BKPyVAN.

The report underscores that late-onset BKPyVAN can occur even without intensified immunosuppression and may lead to significant allograft injury. The authors note that this challenges the assumption that BKPyVAN typically occurs early post-transplant or only with heavy immunosuppression.

Limitations include the small sample size (2 cases), which limits generalizability. As a case report, the evidence level is low, but it provides clinical insight into mechanisms of late-onset BKPyVAN. The association between late-onset BKPyV infection and allograft dysfunction is noted in these cases.

For clinicians, this report suggests that BKPyVAN should be considered in kidney transplant recipients presenting with allograft dysfunction even years after transplant, regardless of immunosuppression intensity. However, these findings are preliminary and require confirmation in larger studies.

How this fits prior evidence

This case report extends prior coverage on immunosuppression in kidney transplant. Earlier items noted that steroid avoidance may reduce death and diabetes but raises rejection risk, and that a guideline narrative review discussed diabetes risks from immunosuppressive therapy. The current report adds that late-onset BKPyVAN can occur without intensified immunosuppression, highlighting a potential complication of standard dual therapy with tacrolimus and mycophenolic acid. It contrasts with the terminated CFZ533 vs tacrolimus trial, which did not report BKPyVAN outcomes.

A new case report describes two kidney transplant recipients who developed a late form of BK polyomavirus-associated nephropathy (BKPyVAN) years after their transplant. One patient was diagnosed 9 years after transplant, the other after 3 years. Neither had been on unusually strong immune suppression at the time. Both had been taking standard dual therapy with tacrolimus and mycophenolic acid.

The virus caused a gradual decline in kidney function in both patients, even after doctors reduced their immunosuppression. One patient also had cytomegalovirus colitis, another viral complication. The report suggests that BK virus can cause kidney damage even without high levels of immune suppression, and that it can appear many years after transplant.

This is a case series with only two patients, so the findings may not apply to all kidney transplant recipients. The report does not prove that the virus caused the kidney decline, but it shows a link. The authors note that doctors should be aware that BK virus can cause late-onset kidney problems.

For now, kidney transplant recipients should continue their regular follow-up care and report any changes in kidney function to their doctor. More research is needed to understand how common this late-onset form is and how best to manage it.

What this means for you:
BK virus can damage kidney transplants years later, even without strong immune suppression.

Common questions

What is BK polyomavirus-associated nephropathy?

It is a kidney infection caused by BK virus that can damage the transplanted kidney. In this report, it occurred 3 and 9 years after transplant.

Who is at risk for late-onset BKPyVAN?

Kidney transplant recipients on standard immunosuppression like tacrolimus and mycophenolic acid may be at risk, even years after transplant.

What were the main findings of this case report?

Two patients developed BK virus kidney damage years after transplant without high immune suppression. Both had gradual kidney function decline.

Is this finding common?

This is a small case series of only two patients, so it is not known how common late-onset BKPyVAN is. More research is needed.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BK polyomavirus–associated nephropathy (BKPyVAN) results from primary infection or reactivation of BK polyomavirus (BKPyV) and remains a significant complication in kidney transplant recipients, contributing to allograft dysfunction and premature allograft loss. Most cases occur within the first 2 years post-transplant, when cell-mediated immunity is most suppressed due to induction immunosuppression. Here, we describe two unusual cases of late-onset BKPyVAN occurring in the absence of intensified immunosuppression and provide a review of potential mechanisms underlying its development in kidney transplant recipients. In the first patient, BKPyVAN developed 9 years after transplantation during maintenance dual immunosuppression with tacrolimus and mycophenolic acid, without prior rejection episodes or exposure to intensified immunosuppression. In the second patient, BKPyVAN first occurred 3 years post-transplant in the setting of concomitant cytomegalovirus colitis, also during dual immunosuppression with tacrolimus and mycophenolic acid. Despite reduction of immunosuppression, BKPyVAN persisted at 1-year follow-up and was associated with a gradual decline in allograft function. These cases highlight that late-onset BKPyVAN may develop even without intensified immunosuppression and can lead to significant allograft injury. Improved strategies are needed to identify patients at risk for late-onset BKPyVAN and to optimize therapeutic management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.